Effect of Helicobacter pylori eradication on oncogenes and cell proliferation

• Published in: European journal of clinical investigation 2008-09, Vol.38 (9), p.628-633
• Main Authors: Zhu, Y., Shu, X., Chen, J., Xie, Y., Xu, P., Huang, D.-Q., Lu, N.-H.
• Format: Article
• Language: English
• Subjects: Adult; Aged; Bacterial diseases; Bacterial diseases of the digestive system and abdomen; Biological and medical sciences; c-myc; Cell Proliferation - drug effects; eradication therapy; Female; Gastric Mucosa - pathology; Gastritis, Atrophic - drug therapy; Gastritis, Atrophic - genetics; Gene Expression; General aspects; Helicobacter Infections - drug therapy; Helicobacter Infections - genetics; Helicobacter Infections - pathology; Helicobacter pylori; Human bacterial diseases; Humans; Immunohistochemistry; Infectious diseases; Male; Medical sciences; Middle Aged; Oncogenes - drug effects; proliferating cell nuclear antigen; Proliferating Cell Nuclear Antigen - metabolism; RNA - metabolism; Telomerase - metabolism; telomerase reverse transcriptase; telomerase RNA; Treatment Outcome
• ISSN: 0014-2972; 1365-2362
• DOI: 10.1111/j.1365-2362.2008.01987.x

Background  Helicobacter pylori , the main cause of chronic gastritis, is a class 1 gastric carcinogen. However, it remains unclear whether H. pylori affects molecular alterations in chronic gastritis. Thus, this study was designed to investigate the effect of H. pylori eradication on the expression of human telomerase RNA (hTR), human telomerase reverse transcriptase (hTERT), c‐myc and proliferation nuclear cell antigen (PCNA) in H. pylori associated chronic gastritis. Materials and methods  hTR was determined by in situ hybridization, hTERT, c‐myc and PCNA were detected by immunohistochemistry using stomach tissues obtained from 39 H. pylori‐infected and 21 H. pylori‐negative patients with chronic gastritis before and after H. pylori eradication therapy or treatment for symptom relief only. Results  Levels of hTR, hTERT, c‐myc and PCNA were significantly higher in H. pylori‐infected mucosa (51·3%, 53·8%, 53·8% and 16·8 ± 5·8, respectively) when compared to H. pylori‐negative mucosa before therapy (19·0%, 23·8%, 28·6%, 8·8 ± 3·4, respectively; P